本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Landos Biopharma, Inc.

22.93
0.0000
成交量:- -
成交額:- -
市值:7,167.55萬
市盈率:-5.74
高:22.93
開:22.93
低:22.93
收:22.93
52周最高:22.93
52周最低:22.93
股本:312.58萬
流通股本:132.89萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-3.9954
每股收益(LYR):-3.4951
淨資產收益率:-70.67%
總資產收益率:-39.38%
市淨率:3.10
市盈率(LYR):-6.56

資料載入中...

2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/23

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/09

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/16

[修訂]年度報告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/04/10

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/10

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/25

重要事件披露

Form 8-K - Current report
2024/03/21

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/21

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/21

重要事件披露

Form 8-K - Current report
2024/02/15

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/04

重要事件披露

Form 8-K - Current report
2023/11/21

重要事件披露

Form 8-K - Current report
2023/11/09

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

重要事件披露

Form 8-K - Current report